Monday, March 18, 2024, San Diego, California, 6:30 AM – 8:00 AM Pacific Time (9:30 AM – 11:00 AM Eastern Time)

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Ovarian Cancer

Part 1 of a 2-Part CME Symposium Series Held in Conjunction with the 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer®

Location
San Diego Convention Center
111 Harbor Drive
San Diego, California
Phone: (619) 525-5000

Program Schedule — Pacific Time
6:00 AM – 6:30 AM — Registration
and Breakfast Buffet
6:30 AM – 8:00 AM — Educational Meeting

Meeting Room
Room 30 ABCDE (Upper Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.  
 
Faculty
Joyce F Liu, MD, MPH
Associate Chief and Director of Clinical Research
Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Mansoor Raza Mirza, MD
Chief Oncologist
Copenhagen University Hospital
Medical Director
Nordic Society of Gynaecological Oncology – Clinical Trial Unit
Vice President, European Society of Gynaecological Oncology
Copenhagen, Denmark


David M O'Malley, MD
Director and Professor
Division of Gynecologic Oncology in Obstetrics and Gynecology
John G Boutselis Chair in Gynecologic Oncology
The Ohio State University and The James Comprehensive Cancer Center
Columbus, Ohio

Moderator
Kathleen N Moore, MD, MS
Deputy Director
Associate Director, Clinical Research
Virginia Kerley Cade Chair in Developmental Therapeutics
Co-Director, Cancer Therapeutics Program
Stephenson Cancer Center at the University of Oklahoma HSC
Associate Director, GOG Partners
Board of Directors, GOG Foundation
Oklahoma City, Oklahoma


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, Merck, and Mural Oncology Inc.
Program Schedule — Pacific Time
6:00 AM – 6:30 AM — Registration and Breakfast Buffet
6:30 AM – 8:00 AM — Educational Meeting

MODULE 1: Current Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Liu

  • Clinical significance of somatic and germline BRCA mutations and homologous recombination deficiency status for treatment decision-making in advanced OC; optimal approaches to biomarker testing for patients with newly diagnosed disease
  • Similarities and differences among the designs and eligibility criteria of the Phase III SOLO-1, PAOLA-1, PRIMA and PRIME trials evaluating maintenance therapy with PARP inhibitor-based regimens after front-line platinum-based therapy
  • Long-term efficacy and safety outcomes from the SOLO-1, PAOLA-1, PRIMA and PRIME trials
  • Optimal integration of up-front PARP inhibitor maintenance into treatment; use of clinical characteristics and other factors to select among available PARP inhibitor-based maintenance strategies
  • Efficacy and safety findings from the Phase II OVARIO study with maintenance niraparib/bevacizumab after front-line platinum-based chemotherapy/bevacizumab for patients with advanced OC; ongoing Phase III evaluation and potential role in clinical settings

MODULE 2: Potential Role of Immunotherapeutic Strategies for Advanced OC — Dr O’Malley

  • Biological rationale for combining PARP inhibitors with anti-PD-1/PD-L1 antibodies with or without bevacizumab for OC
  • Published results from early-phase studies evaluating PARP inhibitors combined with anti-PD-1/PD-L1 antibodies with or without bevacizumab for patients with advanced OC
  • Design, eligibility criteria and major efficacy and safety findings from the Phase III DUO-O study of up-front durvalumab in combination with chemotherapy and bevacizumab followed by durvalumab, bevacizumab and olaparib as maintenance therapy
  • Other ongoing Phase III research efforts evaluating PARP inhibitors in combination with immune checkpoint inhibitors for advanced OC, such as FIRST, ATHENA-COMBO and KEYLYNK-001
  • Mechanism of action of the novel engineered cytokine nemvaleukin alfa; activity and safety observed with this agent in combination with pembrolizumab in the platinum-resistant OC cohort of the Phase I/II ARTISTRY-1 study
  • Design, eligibility criteria and primary and secondary endpoints of the Phase III ARTISTRY-7 trial of nemvaleukin alfa/pembrolizumab versus chemotherapy for platinum-resistant advanced OC; estimated completion date

MODULE 3: Incorporation of Novel Therapies into the Management of Relapsed/Refractory OC — Dr Moore

  • Long-term follow-up from pivotal trials evaluating PARP inhibitors for platinum-sensitive and platinum-resistant recurrent OC; implications of updated indications for these agents in treating relapsed disease
  • Clinical utility and rational use of rechallenge with a PARP inhibitor for patients who have experienced disease progression on or after prior PARP inhibitor therapy
  • Available efficacy and safety data, including recently published findings from the Phase III MIRASOL trial, with mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant OC
  • Ongoing evaluation of mirvetuximab soravtansine for platinum-sensitive OC; emerging positive findings from the Phase II PICCOLO trial
  • Frequency of HER2 expression in advanced OC; outcomes observed in the cohort of patients with OC in the Phase II DESTINY-PanTumor02 trial of trastuzumab deruxtecan (T-DXd) for pretreated HER2-expressing solid tumors
  • Current nonresearch role, if any, of T-DXd in the treatment of HER2-positive advanced OC
  • Frequency of cadherin 6 (CDH6) overexpression in OC; early research findings with the novel CDH6-directed antibody-drug conjugate raludotatug deruxtecan

MODULE 4: Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC — Dr Mirza

  • Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors among patients with OC
  • Reported risk of long-term, serious side effects with PARP inhibitor therapy, such as acute myeloid leukemia and myelodysplastic syndromes
  • Initial dosing of approved PARP inhibitors and appropriate dose-modification strategies for patients experiencing treatment-related toxicity
  • Pathogenesis and incidence of ocular adverse reactions associated with mirvetuximab soravtansine, such as visual impairment, keratopathy, dry eye, photophobia, eye pain and uveitis
  • Recommended approaches to monitoring, preventing and ameliorating ocular toxicities with mirvetuximab soravtansine
  • Spectrum, frequency, severity and timing of onset of other side effects in patients receiving mirvetuximab soravtansine, such as peripheral neuropathy, pneumonitis and gastrointestinal toxicity
  • Monitoring and management techniques for nonocular adverse events with mirvetuximab soravtansine

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of ovarian cancer (OC).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC, and provide appropriate counsel regarding personalized treatment recommendations.
  • Assess available clinical trial data with and newly adapted indications for the use of FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC in order to optimally and appropriately incorporate these agents into current management algorithms.
  • Evaluate the biological rationale for and published research data with PARP inhibitors in combination with other systemic therapies, and consider the current and future clinical and research implications of these findings for OC management.
  • Appraise biological and patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
  • Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal methods of testing for this newly relevant biomarker and the current role of novel approaches in therapeutically exploiting it.
  • Appreciate the side effects associated with various systemic therapies commonly employed in the management of OC, and use this information to develop supportive care plans for patients who receive these agents.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for OC, and appropriately counsel patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Liu — Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, GSK, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Regeneron Pharmaceuticals Inc, Zentalis Pharmaceuticals; Consulting Agreement: Bristol Myers Squibb; Trial Support to My Institution for Study Conduct: Aravive Inc, Arch Oncology, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Clovis Oncology, GSK, Impact Therapeutics, Regeneron Pharmaceuticals Inc, Seagen Inc, Vigeo Therapeutics, Volastra Therapeutics Inc, Zentalis Pharmaceuticals. Dr Mirza — Advisory Committees: Allarity Therapeutics, BIOCAD, BioNTech SE, Daiichi Sankyo Inc, Eisai Inc, GSK, Karyopharm Therapeutics, Merck, Mersana Therapeutics Inc, MSD, Zai Lab; Consulting Agreements: Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, BIOCAD, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Karyopharm Therapeutics, Merck, Mersana Therapeutics Inc, MSD, Novartis, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, Zai Lab; Stock Options/Stock — Public Companies: Karyopharm Therapeutics, Sera Prognostics. Dr O'Malley — Advisory Committees and Consulting Agreements (Personal Fees): AbbVie Inc, Adaptimmune, Agenus Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Duality Biologics, Eisai Inc, Elevar Therapeutics, Exelixis Inc, F Hoffmann-La Roche Ltd, Genelux Corporation, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Imvax Inc, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, OncoC4, Onconova Therapeutics Inc, Regeneron Pharmaceuticals Inc, Replimune, Roche Diagnostics, R-Pharm US, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Clovis Oncology, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, MSD, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Rubius Therapeutics, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Nonrelevant Financial Relationships: GOG Foundation Inc, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG, SWOG.

MODERATOR — Dr Moore — Advisory Committees: Aadi Bioscience, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Caris Life Sciences, Clovis Oncology, Duality Biologics, Eisai Inc, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Janssen Biotech Inc, Lilly, Merck, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, Panavance Therapeutics, Regeneron Pharmaceuticals Inc, VBL Therapeutics, Verastem Inc, Zentalis Pharmaceuticals; Consulting Agreements: Aadi Bioscience, Caris Life Sciences, Duality Biologics, Eisai Inc, Mersana Therapeutics Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Genentech, a member of the Roche Group, GSK, Lilly, PTC Therapeutics.

VIDEO PARTICIPANTS — Deborah K Armstrong, MD — Consulting Agreement (Uncompensated Consulting): Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Eisai Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP. Floor J Backes, MD — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, BioNTech SE, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, GSK, ImmunoGen Inc, Merck. Rachel N Grisham, MD — Consulting Agreements: AstraZeneca Pharmaceuticals LP, GSK, Myriad Genetic Laboratories Inc, Natera Inc; Contracted Research: Context Therapeutics, Corcept Therapeutics, Pfizer Inc, SpringWorks Therapeutics Inc, Verastem Inc. Ritu Salani, MD, MBA — Advisory Committees: Eisai Inc, GSK, ImmunoGen Inc, Merck, Regeneron Pharmaceuticals Inc, Seagen Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, Merck, and Mural Oncology Inc.

San Diego Convention Center
111 Harbor Drive
San Diego, CA 92101
Phone: (619) 525-5000

Meeting Room
Room 30 ABCDE (Upper Level)

Directions
The San Diego Convention Center is the main venue for the 2024 SGO Annual Meeting on Women’s Cancer.

Parking
Discounted parking will be available for 2024 GMO Conference attendees as follows: A charge of $25.00 plus tax per car, per night applies for valet parking. A charge of $20.00 plus tax per car, per night applies for self-parking. Guests are permitted unlimited in-and-out privileges for both self and valet parking. Daily parking is $10.00 plus tax per car for 0 to 3 hours, $12.50 plus tax per car for 3 to 6 hours and $22.50 plus tax per car for 6 hours or more. Prices are subject to change. Please note that unfortunately, due to regulatory reporting requirements, Research To Practice is unable to validate parking. 

This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of ovarian cancer.

There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2024 SGO Annual Meeting on Women’s Cancer.

IN-PERSON Registration for clinicians in practice/healthcare professionals

Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 6:00 AM PDT on Monday, March 18th. If you are interested in attending, please visit our registration desk outside the Room 30 ABCDE (Upper Level) at the San Diego Convention Center (111 Harbor Drive). Please note: Seats will be offered on a first come, first served basis, and onsite registration does not guarantee participation in the meal service. Clinicians in practice will be prioritized for seating first.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.